[go: up one dir, main page]

HUP0201222A3 - Use of soluble constimulatory molecules to enhance immune responses - Google Patents

Use of soluble constimulatory molecules to enhance immune responses

Info

Publication number
HUP0201222A3
HUP0201222A3 HU0201222A HUP0201222A HUP0201222A3 HU P0201222 A3 HUP0201222 A3 HU P0201222A3 HU 0201222 A HU0201222 A HU 0201222A HU P0201222 A HUP0201222 A HU P0201222A HU P0201222 A3 HUP0201222 A3 HU P0201222A3
Authority
HU
Hungary
Prior art keywords
soluble
immune responses
enhance immune
constimulatory molecules
constimulatory
Prior art date
Application number
HU0201222A
Other languages
Hungarian (hu)
Original Assignee
Genetics Inst Llc Delaware All
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst Llc Delaware All filed Critical Genetics Inst Llc Delaware All
Publication of HUP0201222A2 publication Critical patent/HUP0201222A2/en
Publication of HUP0201222A3 publication Critical patent/HUP0201222A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
HU0201222A 1999-05-06 2000-05-05 Use of soluble constimulatory molecules to enhance immune responses HUP0201222A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13294499P 1999-05-06 1999-05-06

Publications (2)

Publication Number Publication Date
HUP0201222A2 HUP0201222A2 (en) 2002-08-28
HUP0201222A3 true HUP0201222A3 (en) 2004-07-28

Family

ID=22456295

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201222A HUP0201222A3 (en) 1999-05-06 2000-05-05 Use of soluble constimulatory molecules to enhance immune responses

Country Status (15)

Country Link
EP (1) EP1181053A2 (en)
JP (1) JP2002544170A (en)
KR (1) KR20020001865A (en)
CN (1) CN1377279A (en)
AU (1) AU4825700A (en)
BR (1) BR0010711A (en)
CA (1) CA2373256A1 (en)
CZ (1) CZ20013964A3 (en)
HK (1) HK1041810A1 (en)
HU (1) HUP0201222A3 (en)
IL (1) IL146106A0 (en)
NO (1) NO20015396L (en)
PL (1) PL360915A1 (en)
WO (1) WO2000067788A2 (en)
ZA (1) ZA200109376B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
JP3871503B2 (en) 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
JP4210454B2 (en) 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
JP3597140B2 (en) 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
JP4212278B2 (en) 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
KR101294455B1 (en) * 2005-06-30 2013-08-07 에자이 알앤드디 매니지먼트 가부시키가이샤 Compounds for preparing immunological adjuvant
US20070172504A1 (en) 2005-12-08 2007-07-26 University Of Lousville Research Foundation, Inc. In vivo cell surface engineering
MX2008007287A (en) 2005-12-08 2008-10-27 Univ Louisville Res Found Methods and compositions for expanding t regulatory cells.
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
AU2013243922A1 (en) * 2012-04-02 2014-10-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
HK1252348A1 (en) 2015-05-06 2019-05-24 Uti Limited Partnership Nanoparticle compositions for sustained therapy
JP7436372B2 (en) 2017-11-29 2024-02-21 ユーティアイ・リミテッド・パートナーシップ How to treat autoimmune diseases
CN110743006B (en) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 Composition for synergistically relieving immune cell failure and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521053A (en) * 1998-07-28 2002-07-16 マイクロメット アーゲー Heteromini body

Also Published As

Publication number Publication date
WO2000067788A2 (en) 2000-11-16
JP2002544170A (en) 2002-12-24
EP1181053A2 (en) 2002-02-27
NO20015396D0 (en) 2001-11-05
AU4825700A (en) 2000-11-21
ZA200109376B (en) 2003-03-13
CA2373256A1 (en) 2000-11-16
HUP0201222A2 (en) 2002-08-28
HK1041810A1 (en) 2002-07-26
KR20020001865A (en) 2002-01-09
WO2000067788A3 (en) 2001-04-05
IL146106A0 (en) 2002-07-25
NO20015396L (en) 2002-01-02
PL360915A1 (en) 2004-09-20
CN1377279A (en) 2002-10-30
CZ20013964A3 (en) 2002-06-12
BR0010711A (en) 2002-02-13

Similar Documents

Publication Publication Date Title
HUP0201222A3 (en) Use of soluble constimulatory molecules to enhance immune responses
AU4835001A (en) Antibodies to human cd154
IL144578A0 (en) Antibodies specific to kdr and uses thereof
GB2357144B (en) Differential delay-time refraction tomography
AU1449401A (en) Method using prior activities to improve the completion of transaction
HUP0302352A3 (en) Sn-38 lipid complexes and methods of use
HUP0105096A3 (en) Preparation of iodixanol
IL153721A0 (en) Antibodies to human mcp-1
IL149614A0 (en) Novel use of antibodies as vaccines
IL145135A0 (en) Use of 13c-nmr to detect binding
GB0029847D0 (en) Preparation of spheroids
AU3179999A (en) Methods to treat undesirable immune responses
GB0130573D0 (en) Improvements to leg supports
IL157614A0 (en) Uses of opg ligand to modulate immune responses
AU5878600A (en) Novel chitosan-containing liquid compositions and methods for their preparation and use
AU5801398A (en) The use of cd4-binding small molecules to inhibit immune responses
PL355845A1 (en) Substituted isoquinoline derivatives and their use as inticonvulsants
HUP0103960A3 (en) Methods of downmodulating the immune response to therapeutic proteins
GB2353217B (en) Use of ribose to treat fibromyalgia
AU2001261133A1 (en) Detection of antibodies to gangliosides
AU6019599A (en) Use of mcrp to enhance immune responses
EP1071459A4 (en) Methods to provoke anti-cancer immune responses
AU4332900A (en) Use of interleukin-11 to treat gastrointestinal disorders
AU2001281151A1 (en) Rhabdovirus-based vectors to express high levels of functional human antibodies
SI1229936T1 (en) Use of anti-idiotypical antibodies as vaccines against cancer